Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and …
Full NVS analysis →
Competitive advantage assessment
Key strengths
Margins Consistently Above PeersGross margin at 75.8% (top 22%) and operating margin at 31.1% (top 17%) indicate strong pricing power.
Scale Supporting ProfitabilityProfitability at scale is strong (score 0.81), demonstrating competitive advantages.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Novartis AG ranks #2 of 20
scored companies in Drug Manufacturers - General by moat score — the top 10%.
The widest moat in the group is Novo Nordisk A/S (NVO)
at 74/100.
Moat scores for companies ranked near NVS in Drug Manufacturers - General
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 67
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 71
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 66
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 68
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 88
· 15% of the moat score
Scale matters only when it converts into economics.
Novartis AG (NVS) scores 72 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #2 of 20 scored companies in Drug Manufacturers - General, the top 10%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 19 companies in Drug Manufacturers - General. Its strongest defense is Scale & Market Position (88/100) and its weakest is Capital Efficiency (66/100).
How does Novartis AG compare with other Drug Manufacturers - General companies?
Novartis AG ranks #2 of 20 scored companies in Drug Manufacturers - General by moat score. The widest moat in Drug Manufacturers - General is Novo Nordisk A/S (NVO) at 74/100. The companies ranked closest are Novo Nordisk A/S (NVO) at 74 just above it and Gilead Sciences, Inc. (GILD) at 70 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 19 companies in Drug Manufacturers - General. The defenses are then weighted to produce the overall score out of 100.
Why is Novartis AG scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Novartis AG?
The Corporate Default template measures 6 defenses, and NVS scores: Pricing Power (73), Cost Advantage (67), Customer Stickiness (71), Capital Efficiency (66), Resilience (68), Scale & Market Position (88). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.